A REVIEW OF ARTIFICIAL INTELLIGENCE IN TREATMENT OF COVID-19

被引:1
作者
Gandla, Kumaraswamy [1 ]
Reddy, Konatham Teja Kumar [2 ]
Babu, Penke Vijaya [3 ]
Sagapola, Rajinikanth [4 ]
Sudhakar, Peta [5 ]
机构
[1] Chaitanya Deemed Be Univ, Dept Pharmaceut Anal, Hanumakonda, Telangana, India
[2] Osmania Univ, Dept Pharm, Univ Coll Technol, Main Rd, Hyderabad, Telangana, India
[3] Dr Reddys Inst Life Sci, Univ Hyderabad Campus, Hyderabad 500046, India
[4] Rowan Univ, Pharmaceut Sci, Glassboro, NJ 08028 USA
[5] St Pauls Coll Pharm, Hyderabad 501510, India
关键词
Artificial imtelligence; COVID-19; Precision; PROPENSITY SCORE; PHARMACOLOGICAL-PROPERTIES; DRUG DISCOVERY; SARS-COV-2; HEALTH; INFECTION; BACK;
D O I
10.47750/pnr.2022.13.S01.31
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug repurposing, also known as repositioning, is a technique in which existing drugs are repurposed to treat emerging and complex diseases like COVID-19. Because of the potential for shorter development timelines and lower overall costs, drug repurposing has emerged as a promising strategy. In the significant data era, artificial intelligence (AI) and network medicine provide cutting-edge information science applications to define disease, medicine, therapeutics, and identify targets with the smallest error. We present guidelines for using AI to accelerate drug repurposing or repositioning, for which AI approaches are formidable and required in this Review. We discuss how to use AI models in precision medicine, such as how AI models can accelerate COVID-19 drug repurposing. Rapidly developing, powerful, and innovative AI and network medicine technologies can help to accelerate therapeutic development. This Review makes a strong case for using artificial intelligence-powered assistive tools to reptupose medications for human disease, including during the COVID-19 pandemic.
引用
收藏
页码:254 / 264
页数:11
相关论文
共 79 条
[1]   Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data [J].
Aliper, Alexander ;
Plis, Sergey ;
Artemov, Artem ;
Ulloa, Alvaro ;
Mamoshina, Polina ;
Zhavoronkov, Alex .
MOLECULAR PHARMACEUTICS, 2016, 13 (07) :2524-2530
[2]   The $2.6 Billion Pill - Methodologic and Policy Considerations [J].
Avorn, Jerry .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20) :1877-1879
[3]   Randomized Clinical Trials and COVID-19 Managing Expectations [J].
Bauchner, Howard ;
Fontanarosa, Phil B. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (22) :2262-2263
[4]   Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model [J].
Beck, Bo Ram ;
Shin, Bonggun ;
Choi, Yoonjung ;
Park, Sungsoo ;
Kang, Keunsoo .
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2020, 18 :784-790
[5]  
Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI [10.1056/NEJMoa2007764, 10.1056/NEJMc2022236]
[6]  
Bordes A., 2013, NIPS'13, P1
[7]   HEALTH CARE in the Age of Interoperability [J].
Braunstein, Mark L. .
IEEE PULSE, 2018, 9 (06) :24-27
[8]  
Cheng Feixiong, 2020, Cleve Clin J Med, DOI 10.3949/ccjm.87a.ccc037
[9]   Network-based prediction of drug combinations [J].
Cheng, Feixiong ;
Kovacs, Istvan A. ;
Barabasi, Albert-Laszlo .
NATURE COMMUNICATIONS, 2019, 10 (1)
[10]   Network-based approach to prediction and population-based validation of in silico drug repurposing [J].
Cheng, Feixiong ;
Desai, Rishi J. ;
Handy, Diane E. ;
Wang, Ruisheng ;
Schneeweiss, Sebastian ;
Barabasi, Albert-Laszlo ;
Loscalzo, Joseph .
NATURE COMMUNICATIONS, 2018, 9